Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan:181:103900.
doi: 10.1016/j.critrevonc.2022.103900. Epub 2022 Dec 21.

Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

Marianna Sirico  1 , Alessandra Virga  2 , Benedetta Conte  3 , Milena Urbini  2 , Paola Ulivi  2 , Caterina Gianni  1 , Filippo Merloni  1 , Michela Palleschi  1 , Marco Gasperoni  4 , Annalisa Curcio  4 , Debjani Saha  5 , Giuseppe Buono  6 , Montserrat Muñoz  7 , Ugo De Giorgi  1 , Francesco Schettini  7
Affiliations
Free article
Review

Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

Marianna Sirico et al. Crit Rev Oncol Hematol. 2023 Jan.
Free article

Erratum in

Abstract

Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.

Keywords: Biomarker; Breast cancer; Endocrine receptor; Endocrine therapy; Ki67; Neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest MP, received advisory board fees from Novartis. GB received honoraria or speaker’s fee from Novartis, GSK, Eli-Lilly, Pfizer, Astra-Zeneca, Roche and Genetic Spa. UDG received honoraria for advisory boards or invited speaker fees from Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, Roche, Clovis, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. The other authors declare no conflict of interests.

Substances